Quarterly report pursuant to Section 13 or 15(d)

Basis of Presentation and Significant Accounting Policies (Details)

v3.21.2
Basis of Presentation and Significant Accounting Policies (Details)
1 Months Ended 3 Months Ended 6 Months Ended 61 Months Ended
Dec. 11, 2020
Jan. 07, 2020
USD ($)
Dec. 31, 2019
USD ($)
Oct. 31, 2017
USD ($)
May 31, 2017
USD ($)
Jun. 30, 2016
USD ($)
May 31, 2016
USD ($)
Jun. 30, 2021
USD ($)
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
segment
Jun. 30, 2020
USD ($)
Jun. 30, 2021
USD ($)
Dec. 31, 2020
USD ($)
Oct. 31, 2018
Sep. 30, 2018
Dec. 31, 2017
Basis of Presentation and Significant Accounting Policies                                
Reverse stock split conversion ratio 0.1429                              
Accumulated deficit               $ 144,722,860   $ 144,722,860   $ 144,722,860 $ 130,647,485      
Net loss               6,620,576 $ 4,536,818 14,243,716 $ 10,910,238          
Cash, Cash Equivalents, and Short-term Investments               122,500,000   122,500,000   122,500,000        
Derivative warrant liability               37,802   $ 37,802   $ 37,802 $ 33,779      
Number of operating segments | segment                   1            
Goodwill                                
Goodwill, Impairment Loss                   $ 0            
Revenue Recognition                                
Revenue               459,494 $ 593,165 998,139 $ 1,495,045          
Allowable expenses incurred under NIH grant               $ 0.0   $ 30,000.00            
Pelican Therapeutics, Inc.                                
Basis of Presentation and Significant Accounting Policies                                
Ownership interest in subsidiary               85.00%   85.00%   85.00% 85.00%      
Pelican Therapeutics, Inc.                                
Basis of Presentation and Significant Accounting Policies                                
Business Acquisition, Percentage of Voting Interests Acquired                           85.00% 80.00% 80.00%
Grant revenue | Maximum                                
Revenue Recognition                                
Amount Awarded From NIH Grant   $ 224,713                            
Grant revenue | Pelican Therapeutics, Inc.                                
Revenue Recognition                                
Amount awarded from CPRIT grant             $ 15,200,000                  
Revenue                       $ 14,100,000        
Remaining grant amount receivable               $ 1,500,000   $ 1,500,000   $ 1,500,000        
Grant revenue | Pelican Therapeutics, Inc. | Maximum                                
Revenue Recognition                                
Amount awarded from CPRIT grant           $ 15,200,000                    
Grant revenue | Tranche 1 | Pelican Therapeutics, Inc.                                
Revenue Recognition                                
Revenue         $ 1,800,000                      
Grant revenue | Tranche 2 | Pelican Therapeutics, Inc.                                
Revenue Recognition                                
Revenue       $ 6,500,000                        
Grant revenue | Tranche 3 | Pelican Therapeutics, Inc.                                
Revenue Recognition                                
Revenue     $ 5,400,000